Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2024
Discovery & Translation
Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 4, 2020
Distillery Therapeutics
Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies
DISEASE CATEGORY: Musculoskeletal; ophthalmic disease
INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has
INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has
BioCentury | Oct 27, 2016
Targets & Mechanisms
T cell gas, tumor brake
Three studies pump the therapeutic potential of PGC-1α
Items per page:
1 - 10 of 14